1719-76-2

Usage

Uses

N-Isopropylthiourea is used as pharmaceutical intermediate.

InChI:InChI=1/C4H10N2S/c1-3(2)6-4(5)7/h3H,1-2H3,(H3,5,6,7)

Upstream product

• 2253-73-8 isopropyl isothiocyanate 
• 27248-16-4 isopropylammonium thiocyanate 
• 92382-87-1 Diisothiocyanato-phenyl-phosphin-sulfid 
• 75-31-0 isopropylamine 
• 137527-01-6 1-{5-[(E)-Isopropylimino]-4-p-tolyl-4,5-dihydro-[1,2,4]thiadiazol-3-yl}-3-methyl-thiourea 
• 137527-02-7 1-Ethyl-3-{5-[(E)-isopropylimino]-4-p-tolyl-4,5-dihydro-[1,2,4]thiadiazol-3-yl}-thiourea 
• 22283-37-0 N-benzoyl-N’-isopropylthiourea 
• 52599-24-3 N-tert-butyl-N'-isopropylthiourea 
• 64-17-5 ethanol 
• 7664-41-7 ammonia 
• 27248-25-5 4-isothiocyanato-4-methylpentan-2-one 
• 691-61-2 O-2-propyl thiocarbamate 
• 100-41-4 ethylbenzene 

Downstream Products

• 500-92-5 proguanil 
• 93002-44-9 1-isopropyl-5-(4-methoxy-phenyl)-biguanide 
• 95872-06-3 17α-hydroxy-17β-(2-isopropylamino-thiazol-4-yl)-androst-4-en-3-one 
• 93996-13-5 4-amino-3-isopropyl-5-phenyl-3H-thiazol-2-ylideneamine 
• 91566-53-9 2-(isopropylamino)-5-phenylthiazol-4(5H)-one 
• 300832-84-2 ciluprevir 
• 300831-03-2 2-(isopropylamino)thiazole-4-carboxylic acid hydrobromide salt 
• 860344-61-2 3-(2-isopropylamino-thiazol-4-yl)-benzoic acid 
• 68163-74-6 4,5-bis(4-fluorophenyl)-1-isopropylimidazole-2-thiol 
• 1467720-03-1 1-[3-{4-(3-morpholinopropoxy)phenyl}-3-hydroxypropyl]-3-isopropylthiourea 
• 1467720-00-8 1-{3-hydroxy-3-(4-methoxyphenyl)propyl}-3-isopropylthiourea 
• 1467719-96-5 1-{3-(4-fluorophenyl)-3-hydroxypropyl}-3-isopropylthiourea 

Relevant academic research and scientific papers

A COLORANT COMPOUND, AND A COLORANT MATERIAL COMPRISING THE SAME

A disclosure of the present invention includes novel colorant compounds based on triarylmethane structure, methods for preparing the same, and colorant materials comprising the same.

Macrocyclic Inhibitors of Hepatitis C Virus

Compounds of the formula (I): and N-oxides, salts and stereoisomers thereof wherein A is OR1, NHS(═O)pR2, NHR3, NRaRb, C(═O)NHR3 or C(═O)NRaRb wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl or NRaRb; R3 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl, —OC1-C6alkyl, —OC0-C3alkylenecarbocyclyl, —OC0-C3alkyleneheterocyclyl; wherein any alkyl, carbocyclyl or heterocycylyl in R1, R2 or R3 are optionally substituted p is independently 1 or 2; n is 3, 4, 5 or 6; denotes an optional double bond; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Ry and Ry′ are independently C1-C6alkyl; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; W is —CH2—, —O—, —OC(═O)NH—, —OC(═O)—, —S—, —NH—, —NRa, —NHS(═O)2—, —NHC(=0)NH— or —NHC(═O)—, —NHC(═S)NH— or a bond; R8 is an optionally substituted ring system containing 1 or 2 saturated, partially saturated or unsaturated carbo or heterocyclic rings have utility in the inhibition of NS-3 serine proteases, such as flavivirus infections.

Macrocylic Inhibitors of Hepatitis C Virus

Compounds of the formula I: and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(═O)pR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl;R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl;p is independently 1 or 2;n is 3, 4, 5 or 6; — denotes an optional double bond;L is N or CRz; Rz is H or forms a double bond with the asterisked carbon;Rq is H or when L is CRz, Rq can also be C1-C6alkyl;Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl-carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl;R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl;R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV

HCV NS-3 serine protease inhibitors

HCV inhibitors, compositions comprising these compounds as active ingredient, as well as processes for preparing these compounds, having the formula I wherein A is

HCV NS-3 serine protease inhibitors

HCV inhibitors, compositions comprising these compounds as active ingredient, as well as processes for preparing these compounds, of formula: wherein A is

HCV NS-3 SERINE PROTEASE INHIBITORS

Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.

Substituted 5,5′-diphenyl-2-thioxoimidazolidin-4-one as CB 1 cannabinoid receptor ligands: Synthesis and pharmacological evaluation

A set of 30 substituted 5,5′-diphenyl-2-thioxoimidazolidin-4-one (thiohydantoins) derivatives was synthesized, and their affinity for the human CB1 cannabinoid receptor has been evaluated. These compounds are derived from the previously described cannabinoid ligands 5,5′- diphenylimidazolidine-2,4-dione (hydantoins). The replacement of the oxygen by a sulfur leads to an increase of the affinity while the function-i.e., inverse agonism-determined by [35S]-GTPγS experiments remains unaffected. Finally, to evaluate the molecular parameters that could influence the affinity of the thiohydantoins, molecular electrostatic potential as well as lipophilicity calculations were undertaken on representative thiohydantoins and hydantoins derivatives. In conclusion, 5,5′-bis-(4-iodophenyl)-3-butyl-2- thioxoimidazolidin-4-one (31) and 3-allyl-5,5′-bis(4-bromophenyl)-2- thioxoimidazolidin-4-one (32) possess the highest affinity for the CB 1 cannabinoid receptor described to date for the hydantoin and thiohydantoins series when compared in a same bioassay.

1,4,5-Trialkyl imidazole system anti-inflammatory properties of new substituted derivatives

In an investigation of the anti-inflammatory properties of five-membered ring nitrogen-containing heterocyclic compounds, two series of derivatives of imidazole were prepared by altering the sites of substitution and by joining aliphatic chains to the nitrogen atom in the 1 position of the imidazole ring. Some of them were more potent inhibitors of carragenan-induced edema than indomethacin. An electron spin resonance study indicated that these compounds possess anti-radical activity.

Synthesis and antithyroid activity of 1,4,5-trialkyl 2-thioimidazole derivatives

A series of compounds based on the structure of MTI (1-methyl-2-thioimidazole) were synthesized by condensation of α-hydroxyketones and alkylthioureas. The α-hydroxyketones were obtained by a radical reaction in the presence of sodium and the alkyl ester, while the alkylthioureas were prepared by nucleophilic addition of ammonia on an alkylisothiocyanate. The antithyroid activity of the 13 compounds prepared was evaluated in vitro by determination of the concentrations which led to a 50% inhibition (IC50) of the activity of thyroid peroxidase, and in vivo by assay of thyroid hormones levels and histological examination of the thyroid gland in rats treated chronically with the compounds. 1-methyl-4,5-dipropyl 2-thioimidazole (compound 10) was found to have the highest antithyroid activity of the 13 compounds synthesized.

Synthesis and inhibitory effects of 1,4,5-trialkyl-2-thioimidazole derivatives on platelet aggregation

New 1,4,5-trialkyl-2-thioimidazole have been synthesized by the condensation of α-hydroxyketones and alkylthioureas. The in vitro platelet aggregation inhibiting effect of prepared compounds on human platelets was studied in the presence of ADP and collagen as inducers. The formation of thromboxane B2 (TXB2) was inhibited. 1-isopropyl-4,5-dimethyl-2-thioimidazole has the greatest aggregation inhibiting effect, about 4 times that of aspirin. It highly inhibits the production of TXB2 (68,5% for a final concentration of 0,04 M).